Ann: Quarterly Activities Report and Appendix 4C Cash Flow Report, page-16

@RDL – Appreciate the reply, but I don’t think expecting execution before promotion is naïve.In fact, I think it’s the bare minimum for any credible business.If the technology is as revolutionary as claimed – with a durable moat, clinical utility, and an active reimbursement code – then commercial adoption should be the natural next step. Why hasn’t that happened? Why, after all the trials, do we still not have a paying customer base?I get that raising capital is necessary, but raising capital off hype instead of results erodes long-term shareholder trust. Pumping the share price for a cap raise without solid sales only delays the inevitable accountability.

Spending shareholder funds on roadshows and promotional reports (like Evolution Capital’s paid piece) instead of converting pilots into paying customers sends the wrong signal. It shifts focus from execution to optics – which, as a shareholder, concerns me.If the moat is real, if the product solves a real problem, and if reimbursement is already in play – then let the results speak. Execution should be the foundation for valuation, not a post-raise afterthought.